--- title: 'Morning Brief — Friday, September 18, 2026' type: 'episode' url: 'https://doc.social/episodes/morning-brief-2026-09-18' show: 'doc social Morning Brief' show_url: 'https://doc.social/podcasts/morning-brief' published: '2026-09-18' audio: 'https://media.doc.social/podcasts/morning-brief/2026-09-18.mp3' --- # Morning Brief — Friday, September 18, 2026 Mindray launches the SV70 non-invasive ventilator into the fleet-replacement hole Philips left when it exited hospital ventilation · Stryker brings Prophecy patient-specific planning to the Incompass total ankle, plus a Hoffmann LRF smartHEX frame with a patient-facing app, at AOFAS 2026 · SIGNUS USA completes the first US implantation of COSY, its posterior occipito-cervico-thoracic fixation… ## Summary 4 stories this morning, for surgeons and the people who support them. - **Mindray launches the SV70 non-invasive ventilator into the fleet-replacement hole Philips left when it exited hospital ventilation** — Announced September 15, 2026: Mindray North America launched the SV70, a turbine-driven single-limb platform combining non-invasive ventilation with high-flow oxygen therapy, wireless integration with its BeneVision N-Series monitors, and a three-year warranty; it is explicitly built to accept the accessories clinicians already use with the Philips Respironics V60. Philips announced in June 2024 that it was ending sales of hospital ventilation solutions and oxygen concentrators; the V60 and V60 Plus are discontinued with service and parts support running to as late as December 2029, after a Class I recall history over power-management circuit boards (FDA: https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/philips-respironics-recalls-v60-and-v60-plus-ventilators-due-power-management-printed-circuit-board ; Philips: https://www.usa.philips.com/sleep-respiratory-care/news/business-updates/src-portfolio-update). Mindray entered the North American ventilator market in March 2026 with the SV900 and SV700 and describes itself as the world's second-largest acute-care hospital ventilator provider (a company claim). Corroborated by MassDevice, September 17 (https://www.massdevice.com/mindray-looks-to-fill-hospital-ventilator-gap-left-by-philips-exit/) and 24x7 (https://24x7mag.com/medical-equipment/patient-care-equipment/ventilators/mindray-launches-sv70-non-invasive-ventilator-hospitals-replace-withdrawn-philips-v60-fleets/). [Source](https://www.prnewswire.com/news-releases/mindray-north-america-advances-respiratory-care-with-the-launch-of-the-sv70-non-invasive-ventilator-302879161.html) - **Stryker brings Prophecy patient-specific planning to the Incompass total ankle, plus a Hoffmann LRF smartHEX frame with a patient-facing app, at AOFAS 2026** — Announced September 16, 2026 and shown at the AOFAS Annual Meeting in Seattle (booth 601): Prophecy CT-based patient-specific surgical planning now supports the Incompass Total Ankle System, in both resect-through and pin-through fixation configurations. Stryker says Prophecy has been used in more than 100,000 ankle cases over fourteen years; it came to Stryker with the 2020 Wright Medical acquisition, where it was the patient-matched guide path for Wright's total ankles, and Incompass was developed using Prophecy and SOMA (Stryker Orthopaedic Modeling and Analytics) data. Quote from Adam Jacobs, VP/GM Stryker Foot & Ankle. Also shown: Hoffmann LRF smartHEX, a limb-reconstruction external fixation platform with expanded frame components, updated planning software, and a mobile app that carries the surgeon-prescribed correction plan to the patient. Competitive context: Zimmer Biomet's Paragon 28 sells MAVEN patient-specific instrumentation with the APEX 3D total ankle (https://smart.paragon28.com/maven/) and Exactech sells both Vantage Ankle PSI and GPS Ankle navigation (https://www.exac.com/first-surgery-using-the-vantage-ankle-psi-patient-specific-instrumentation/). No comparative trial establishes that PSI improves total ankle alignment outcomes. Also reported by ORTHOWORLD: https://www.orthoworld.com/stryker-to-launch-prophecy-surgical-planning-for-incompass/ [Source](https://orthospinenews.com/2026/09/17/stryker-showcases-foot-ankle-innovation-at-aofas-2026-with-prophecy-surgical-planning-for-incompass-and-hoffmann-lrf-smarthex/) - **SIGNUS USA completes the first US implantation of COSY, its posterior occipito-cervico-thoracic fixation system, with up to 70 degrees of screw angulation** — Reported September 16, 2026: SIGNUS USA completed the first US implantation of the COSY Cervicothoracic-Occipital Rod-Screw Spine Implant System, a modular posterior occipito-cervico-thoracic platform supporting constructs from the occiput through the upper thoracic spine. Features: polyaxial and cervical pedicle screws with up to 70 degrees of angulation, cannulated screw heads, lateral mass / pedicle / C2 pars / translaminar trajectories in a single construct, occipital plates, rods, cross connectors and atlas hook alternatives. It integrates with DIPLOMAT, SIGNUS's posterior thoracolumbar system, which has been on the US market more than a decade, when a construct must extend caudally. The release does not state a specific FDA clearance number. Competitive context: the US OCT segment has been held by Medtronic's Vertex, DePuy Synthes's Mountaineer OCT and Globus Medical's QUARTEX. Also reported by ORTHOWORLD: https://www.orthoworld.com/signus-usa-debuts-cosy-spine-implant/ and in Orthogate's September 17 industry briefing: https://www.orthogate.org/medtech-innovation/industry/84759-orthopaedic-industry-daily-briefing-2026-09-17 [Source](https://bonezonepub.com/2026/09/16/signus-usa-debuts-cosy-spine-implant/) - **Onkos releases the ELEOS Total Femoral Adapter with NanoCept, the first implant coated at its own new New Jersey facility, with human infection-reduction data still pending a Section 522 study** — Announced September 17, 2026: Onkos Surgical released the ELEOS Total Femoral Adapter with NanoCept Antibacterial Technology, extending the silver-based coating from ELEOS midsections used in complex knee and hip reconstruction to total femoral replacement. NanoCept received FDA De Novo authorization in 2024 for use on titanium implants in the ELEOS Limb Salvage System; the supporting data is standardized in-vitro testing showing up to a 99.999% (5-log) kill rate against organisms commonly found in the OR environment, and clinical infection reduction in humans is not established — Onkos previously announced initiation of a Section 522 post-market surveillance study of ELEOS with NanoCept (https://www.prnewswire.com/news-releases/onkos-surgical-announces-initiation-of-522-post-market-surveillance-study-of-the-eleos-limb-salvage-system-with-nanocept-antibacterial-implant-technology-302685719.html). More than 500 patients have received a NanoCept ELEOS implant since its December 2024 introduction. This adapter is the first product produced and coated at Onkos's newly opened NanoCept Innovation Center in Bridgewater, New Jersey, with additional ELEOS products expected within months. Quote from Julia Visgauss, MD, Chief of Orthopaedic Oncology at Duke Health. Also reported by ORTHOWORLD (https://www.orthoworld.com/onkos-launches-eleos-total-femoral-adapter-with-nanocept/) and ODT (https://www.odtmag.com/breaking-news/onkos-rolls-out-eleos-total-femoral-adapter-with-nanocept-antibacterial-tech/). [Source](https://www.prnewswire.com/news-releases/onkos-surgical-expands-access-to-nanocept-antibacterial-technology-for-patients-requiring-total-femoral-replacement-302881384.html) ### Contribute to the Brief Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from [Studio](https://next.doc.social/studio). Not on doc social yet? [Contribute a lecture or join the network](https://next.doc.social/contribute) — doc social is a clinical education platform for clinicians, and this show is one part of it. _Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source._